Next-gen psychedelics developer Biomind Labs Inc. (OTC: BMNDF) shared its unaudited financial results for the three and nine months ended September 30, 2022 and announced that the FDA gave clearance to the company’s Investigational New Drug (IND) application related to New Chemical Entity (NCE) Triptax.

Biomind Labs is developing novel pharma formulations of the main psychedelics DMT, 5-MeO-DMT and mescaline, and is focused on bringing patients and the psychiatric community novel and affordable treatments. CEO Alejandro Antalich stated that the approval is “a paramount achievement” for the company and “a historic moment” within the psychedelic treatments field.

“With this IND clearance, we are now in a strong …

Full story available on